Activation of STING directly triggers cancer cell death in malignant B cells [64], while in triple-negative breast cancer, STING has been shown to have anti-tumor effects by promoting the type-I IFN signaling pathway [65]. This evidence concerns the gene STING1 and triple-negative breast carcinoma.